Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Trial abstract · §5

SUSTAIN-1-REGIONAL-CN — citing documents

Every Institute document that draws on this record.

Document identifier
CEI-TR-0312/5
Series
Trial abstract
Version
1.0
Published
12 Jan 2023
Last reviewed
12 Dec 2023
Next review
12 Dec 2025
Identifier
10.71829/cei.trial.312
Certainty
Very low
Cycle
2023 Q1
Phase
Phase 3
Status
Reported

Institute-constructed programme record. This document is not a report of a published trial. It is a record the Institute has constructed to represent an instalment, sub-study or extension of a real development programme, published in order to carry a methodological point that the parent trial report does not address. No effect estimate on this page is attributable to any publication, and its reference-list entry carries a programme-record label rather than a citation. The policy governing these records was settled through a public comment period.

§5Citing documents

This page records every Institute document that draws on SUSTAIN-1-REGIONAL-CN. A trial abstract is a node in the document set rather than a leaf: it is cited by the monographs that use its estimate and by the syntheses that include it, and those citations are listed here so that the flow of an estimate through the document set can be followed in both directions.

§5.1Monograph evidence extracts

No monograph evidence extract draws on this record.

§5.2Evidence syntheses

No evidence synthesis includes this record among its contributing studies.

§5.3Other records in the same programme

Table 9. Other records in the SUSTAIN — semaglutide in type 2 diabetes.

RecordTypePhaseStatus
SUSTAIN-1Published trial3Reported
SUSTAIN-6Published trial3Reported
SUSTAIN-7Published trial3Reported
SUSTAIN-1-QOLProgramme record3Reported
SUSTAIN-6-BODY-COMPProgramme record3Reported
SUSTAIN-7-BIOMARKERProgramme record3Reported
SUSTAIN-6-REGIONAL-JPProgramme record3Reported
SUSTAIN-7-ADHERENCEProgramme record3Reported
SUSTAIN-1-REGIONAL-JPProgramme record3Reported
SUSTAIN-6-REGIONAL-CNProgramme record3Reported
SUSTAIN-7-OLEProgramme record3Reported
SUSTAIN-1-BODY-COMPProgramme record3Reported
SUSTAIN-6-QOLProgramme record3Reported
SUSTAIN-7-ELDERLYProgramme record3Reported
SUSTAIN-1-DDIProgramme record1Reported
SUSTAIN-7-RENAL-IMPProgramme record1Reported

§5.4Reference

This record is an Institute construction and its reference-list entry says so[1]. The label travels with the reference, which was the substance of a public comment period whose disposition is published in full.

References cited on this page

References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.

  1. Compound Evidence Institute. SUSTAIN-1-REGIONAL-CN — Institute-constructed programme record. Compound Evidence Institute trial register 2023. Institute-constructed programme record

Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.